Pharma BD Deal Intelligence

Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited

2008 · Acquisition/Merger · $4.6B · Complete

Daiichi Sankyo acquired a controlling 63.9% stake in Ranbaxy Laboratories for approximately $4.6 billion, seeking to build a hybrid innovator-generics model and gain access to fast-growing emerging markets, particularly India. The deal later proved problematic due to FDA compliance issues at Ranbaxy facilities.

Key facts

• Announced Jun 11, 2008
• Closed Nov 07, 2008
• Deal value $4.6B
• Deal type Acquisition/Merger
• Therapeutic area Cardiovascular, Gastroenterology, Infectious Disease, Neurology, Oncology
• Key assets Ranbaxy generics portfolio (India, US, EU markets), Global manufacturing network (11 plants across 7 countries), India commercial infrastructure, Branded generics portfolio in emerging markets, First-to-file ANDA positions (including atorvastatin), atorvastatin (generic Lipitor), Generic portfolio
• Mechanism Multiple (generic portfolio), HMG-CoA reductase inhibitor (generic), Fluoroquinolone antibiotic (generic)

← Browse all deals  ·  How we score deals